{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:14:22Z","timestamp":1794507262609,"version":"4.9.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s00066-022-01962-x","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T11:22:39Z","timestamp":1655119359000},"page":"940-948","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Bone-only oligometastatic renal cell carcinoma patients treated with stereotactic body radiotherapy: a multi-institutional study"],"prefix":"10.1007","volume":"198","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2742-9021","authenticated-orcid":false,"given":"Cem","family":"Onal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozan Cem","family":"Guler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pervin","family":"Hurmuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guler","family":"Yavas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak","family":"Tilki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezgi","family":"Oymak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cagdas","family":"Yavas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gokhan","family":"Ozyigit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"key":"1962_CR1","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ctrv.2011.06.011","volume":"38","author":"SL Wood","year":"2012","unstructured":"Wood\u00a0SL, Brown\u00a0JE (2012) Skeletal metastasis in renal cell carcinoma: current and future management options. Cancer Treat Rev 38:284\u2013291. https:\/\/doi.org\/10.1016\/j.ctrv.2011.06.011","journal-title":"Cancer Treat Rev"},{"key":"1962_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray\u00a0F, Ferlay\u00a0J, Soerjomataram\u00a0I et\u00a0al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185\u00a0countries. CA Cancer J Clin 68:394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1962_CR3","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.bone.2010.09.008","volume":"48","author":"E Woodward","year":"2011","unstructured":"Woodward\u00a0E, Jagdev\u00a0S, McParland\u00a0L et\u00a0al (2011) Skeletal complications and survival in renal cancer patients with bone metastases. Bone 48(1):160\u2013166. https:\/\/doi.org\/10.1016\/j.bone.2010.09.008","journal-title":"Bone"},{"issue":"4","key":"1962_CR4","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/annonc\/mdr362","volume":"23","author":"M Bianchi","year":"2012","unstructured":"Bianchi\u00a0M, Sun\u00a0M, Jeldres\u00a0C et al (2012) Distribution of metastatic sites in renal cell carcinoma: a\u00a0population-based analysis. Ann Oncol 23(4):973\u2013980. https:\/\/doi.org\/10.1093\/annonc\/mdr362","journal-title":"Ann Oncol"},{"issue":"12","key":"1962_CR5","doi-asserted-by":"publisher","first-page":"e83026","DOI":"10.1371\/journal.pone.0083026","volume":"8","author":"D Santini","year":"2013","unstructured":"Santini\u00a0D, Procopio\u00a0G, Porta\u00a0C et\u00a0al (2013) Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey. Plos One 8(12):e83026. https:\/\/doi.org\/10.1371\/journal.pone.0083026","journal-title":"Plos One"},{"key":"1962_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13046-015-0122-0","volume":"34","author":"M Santoni","year":"2015","unstructured":"Santoni\u00a0M, Conti\u00a0A, Procopio\u00a0G et\u00a0al (2015) Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis? J\u00a0Exp Clin Cancer Res 34:10. https:\/\/doi.org\/10.1186\/s13046-015-0122-0","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"1962_CR7","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.clgc.2017.01.010","volume":"15","author":"S Kalra","year":"2017","unstructured":"Kalra\u00a0S, Verma\u00a0J, Atkinson\u00a0BJ et\u00a0al (2017) Outcomes of patients with metastatic renal cell carcinoma and bone metastases in the targeted therapy era. Clin Genitourin Cancer 15(3):363\u2013370. https:\/\/doi.org\/10.1016\/j.clgc.2017.01.010","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"1962_CR8","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.eururo.2013.08.012","volume":"65","author":"RR McKay","year":"2014","unstructured":"McKay\u00a0RR, Kroeger\u00a0N, Xie\u00a0W et\u00a0al (2014) Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol 65(3):577\u2013584. https:\/\/doi.org\/10.1016\/j.eururo.2013.08.012","journal-title":"Eur Urol"},{"issue":"12","key":"1962_CR9","doi-asserted-by":"publisher","first-page":"e549","DOI":"10.1016\/S1470-2045(14)70235-9","volume":"15","author":"S Dabestani","year":"2014","unstructured":"Dabestani\u00a0S, Marconi\u00a0L, Hofmann\u00a0F et\u00a0al (2014) Local treatments for metastases of renal cell carcinoma: a\u00a0systematic review. Lancet Oncol 15(12):e549\u2013e561. https:\/\/doi.org\/10.1016\/S1470-2045(14)70235-9","journal-title":"Lancet Oncol"},{"issue":"8","key":"1962_CR10","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41585-018-0034-9","volume":"15","author":"V Grunwald","year":"2018","unstructured":"Grunwald\u00a0V, Eberhardt\u00a0B, al Bex\u00a0A (2018) An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma. Nat Rev Urol 15(8):511\u2013521. https:\/\/doi.org\/10.1038\/s41585-018-0034-9","journal-title":"Nat Rev Urol"},{"issue":"1","key":"1962_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman\u00a0S, Weichselbaum\u00a0RR (1995) Oligometastases. J\u00a0Clin Oncol 13(1):8\u201310. https:\/\/doi.org\/10.1200\/JCO.1995.13.1.8","journal-title":"J Clin Oncol"},{"key":"1962_CR12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2018.04.008","volume":"98","author":"E Meyer","year":"2018","unstructured":"Meyer\u00a0E, Pasquier\u00a0D, Bernadou\u00a0G et\u00a0al (2018) Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: a study of the GETUG group. Eur J Cancer 98:38\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2018.04.008","journal-title":"Eur J Cancer"},{"issue":"1","key":"1962_CR13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijrobp.2017.01.032","volume":"98","author":"CJ Wang","year":"2017","unstructured":"Wang\u00a0CJ, Christie\u00a0A, Lin\u00a0MH et\u00a0al (2017) Safety and efficacy of stereotactic ablative radiation therapy for renal cell carcinoma extracranial metastases. Int J Radiat Oncol Biol Phys 98(1):91\u2013100. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.01.032","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"1962_CR14","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s12094-021-02574-0","volume":"23","author":"G Marvaso","year":"2021","unstructured":"Marvaso\u00a0G, Corrao\u00a0G, Oneta\u00a0O et\u00a0al (2021) Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how? Clin Transl Oncol 23(8):1717\u20131726. https:\/\/doi.org\/10.1007\/s12094-021-02574-0","journal-title":"Clin Transl Oncol"},{"issue":"6","key":"1962_CR15","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10585-021-10131-w","volume":"38","author":"C Franzese","year":"2021","unstructured":"Franzese\u00a0C, Marvaso\u00a0G, Francolini\u00a0G et\u00a0al (2021) The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a\u00a0multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group. Clin Exp Metastasis 38(6):527\u2013537. https:\/\/doi.org\/10.1007\/s10585-021-10131-w","journal-title":"Clin Exp Metastasis"},{"issue":"12 Suppl","key":"1962_CR16","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2519::AID-CNCR26>3.0.CO;2-E","volume":"80","author":"S Ning","year":"1997","unstructured":"Ning\u00a0S, Trisler\u00a0K, Wessels\u00a0BW, Knox\u00a0SJ (1997) Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer 80(12 Suppl):2519\u20132528","journal-title":"Cancer"},{"issue":"20","key":"1962_CR17","doi-asserted-by":"publisher","first-page":"4825","DOI":"10.1088\/0031-9155\/49\/20\/012","volume":"49","author":"M Guerrero","year":"2004","unstructured":"Guerrero\u00a0M, Li\u00a0XA (2004) Extending the linear-quadratic model for large fraction doses pertinent to stereotactic radiotherapy. Phys Med Biol 49(20):4825\u20134835. https:\/\/doi.org\/10.1088\/0031-9155\/49\/20\/012","journal-title":"Phys Med Biol"},{"issue":"1","key":"1962_CR18","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ijrobp.2015.05.016","volume":"93","author":"CW Song","year":"2015","unstructured":"Song\u00a0CW, Lee\u00a0YJ, Griffin\u00a0RJ et al (2015) Indirect tumor cell death after high-dose hypofractionated irradiation: implications for stereotactic body radiation therapy and stereotactic radiation surgery. Int J Radiat Oncol Biol Phys 93(1):166\u2013172. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.05.016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1962_CR19","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ijrobp.2013.07.022","volume":"88","author":"JM Brown","year":"2014","unstructured":"Brown\u00a0JM, Carlson\u00a0DJ, Brenner\u00a0DJ (2014) The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved? Int J Radiat Oncol Biol Phys 88(2):254\u2013262. https:\/\/doi.org\/10.1016\/j.ijrobp.2013.07.022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"1962_CR20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1667\/rr2773.1","volume":"177","author":"HJ Park","year":"2012","unstructured":"Park\u00a0HJ, Griffin\u00a0RJ, Hui\u00a0S et al (2012) Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res 177(3):311\u2013327. https:\/\/doi.org\/10.1667\/rr2773.1","journal-title":"Radiat Res"},{"issue":"2","key":"1962_CR21","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3109\/0284186X.2014.939298","volume":"54","author":"G Kothari","year":"2015","unstructured":"Kothari\u00a0G, Foroudi\u00a0F, Gill\u00a0S et\u00a0al (2015) Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: a systematic review. Acta Oncol 54(2):148\u2013157. https:\/\/doi.org\/10.3109\/0284186X.2014.939298","journal-title":"Acta Oncol"},{"key":"1962_CR22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ctro.2019.04.012","volume":"18","author":"A Ruhle","year":"2019","unstructured":"Ruhle\u00a0A, Andratschke\u00a0N, Siva\u00a0S, Guckenberger\u00a0M (2019) Is there a\u00a0role for stereotactic radiotherapy in the treatment of renal cell carcinoma? Clin Transl Radiat Oncol 18:104\u2013112. https:\/\/doi.org\/10.1016\/j.ctro.2019.04.012","journal-title":"Clin Transl Radiat Oncol"},{"key":"1962_CR23","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13014-015-0528-z","volume":"10","author":"B Altoos","year":"2015","unstructured":"Altoos\u00a0B, Amini\u00a0A, Yacoub\u00a0M et\u00a0al (2015) Local control rates of metastatic renal cell carcinoma (RCC) to thoracic, abdominal, and soft tissue lesions using stereotactic body radiotherapy (SBRT). Radiat Oncol 10:218. https:\/\/doi.org\/10.1186\/s13014-015-0528-z","journal-title":"Radiat Oncol"},{"issue":"4","key":"1962_CR24","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1093\/annonc\/mdq554","volume":"22","author":"B Beuselinck","year":"2011","unstructured":"Beuselinck\u00a0B, Oudard\u00a0S, Rixe\u00a0O et al (2011) Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol 22(4):794\u2013800. https:\/\/doi.org\/10.1093\/annonc\/mdq554","journal-title":"Ann Oncol"},{"issue":"5","key":"1962_CR25","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.euo.2019.05.007","volume":"2","author":"NG Zaorsky","year":"2019","unstructured":"Zaorsky\u00a0NG, Lehrer\u00a0EJ, Kothari\u00a0G et al (2019) Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): A meta-analysis of 28\u00a0studies. Eur Urol Oncol 2(5):515\u2013523. https:\/\/doi.org\/10.1016\/j.euo.2019.05.007","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"1962_CR26","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.ijrobp.2011.02.040","volume":"82","author":"MJ Zelefsky","year":"2012","unstructured":"Zelefsky\u00a0MJ, Greco\u00a0C, Motzer\u00a0R et al (2012) Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys 82(5):1744\u20131748. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.02.040","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1962_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15541","author":"B De","year":"2021","unstructured":"De\u00a0B, Venkatesan\u00a0AM, Msaouel\u00a0P et\u00a0al (2021) Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a\u00a0strategy to defer systemic therapy escalation. BJU Int. https:\/\/doi.org\/10.1111\/bju.15541","journal-title":"BJU Int"},{"issue":"2","key":"1962_CR28","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ijrobp.2019.07.023","volume":"105","author":"Y Zhang","year":"2019","unstructured":"Zhang\u00a0Y, Schoenhals\u00a0J, Christie\u00a0A et\u00a0al (2019) Stereotactic ablative radiation therapy (SAbR) used to defer systemic therapy in oligometastatic renal cell cancer. Int J Radiat Oncol Biol Phys 105(2):367\u2013375. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.07.023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"1962_CR29","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/COC.0b013e31825d52b2","volume":"36","author":"MC Ranck","year":"2013","unstructured":"Ranck\u00a0MC, Golden\u00a0DW, Corbin\u00a0KS et\u00a0al (2013) Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. Am J Clin Oncol 36(6):589\u2013595. https:\/\/doi.org\/10.1097\/COC.0b013e31825d52b2","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"1962_CR30","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.eururo.2021.07.026","volume":"80","author":"P Cheung","year":"2021","unstructured":"Cheung\u00a0P, Patel\u00a0S, North\u00a0SA et\u00a0al (2021) Stereotactic radiotherapy for oligoprogression in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor therapy: A phase 2 prospective multicenter study. Eur Urol 80(6):693\u2013700. https:\/\/doi.org\/10.1016\/j.eururo.2021.07.026","journal-title":"Eur Urol"},{"issue":"10","key":"1962_CR31","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1093\/jnci\/djz101","volume":"111","author":"KL Spencer","year":"2019","unstructured":"Spencer\u00a0KL, van der Velden\u00a0JM, Wong\u00a0E et\u00a0al (2019) Systematic review of the role of stereotactic radiotherapy for bone metastases. J\u00a0Natl Cancer Inst 111(10):1023\u20131032. https:\/\/doi.org\/10.1093\/jnci\/djz101","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"1962_CR32","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.ijrobp.2008.02.060","volume":"71","author":"A Sahgal","year":"2008","unstructured":"Sahgal\u00a0A, Larson\u00a0DA, Chang\u00a0EL (2008) Stereotactic body radiosurgery for spinal metastases: a\u00a0critical review. Int J Radiat Oncol Biol Phys 71(3):652\u2013665. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.02.060","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-022-01962-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-022-01962-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-022-01962-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T11:17:46Z","timestamp":1664277466000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-022-01962-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1962"],"URL":"https:\/\/doi.org\/10.1007\/s00066-022-01962-x","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,13]]},"assertion":[{"value":"31 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.\u00a0Onal, O.C.\u00a0Guler, P.\u00a0Hurmuz, G.\u00a0Yavas, B.\u00a0Tilki, E.\u00a0Oymak, C.\u00a0Yavas, and G.\u00a0Ozyigit declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}